Email Us
Call Us
Altogen Labs is now offering expedited PCR analysis services for most variants of COVID-19, including the highly transmissible Omicron variant. Results are guaranteed the next day. The price for this service is $250. Altogen Labs offers PCR tests only. How does it work? Submitting your sample for PCR testing at Altogen Labs is done at… Continue Reading
News
Characterizing Novel Inhibitor Activity
Publication [Download PDF]: Alexandra Tyulyandina, Daniel Harrison, Wei Yin, et al. Invest New Drugs 35: 127–133. doi: 10.1007/s10637-016-0400-5 Based on data from 2013-2015, about 38% of the population will be diagnosed with some type of cancer during their lifetime, and there is an ongoing need for improved treatment techniques. Some chemotherapy agents are specific to… Continue Reading
Altogen Xenograft Model in a KRAS Pancreatic Adenocarcinoma Study
Publication [Download PDF]: KRAS mutant allele-specific expressionknockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex by Donald D. Rao et al. PLOS ONE https://doi.org/10.1371/journal.pone.0193644 Pancreatic cancer is notorious for its poor prognosis caused by early metastasis potential. While cancer biology has obtained a deeper understanding of biochemical, micro-environmental, genetic and epigenetic occurrences in… Continue Reading
How to test plant extract toxicity?
This is a general outline, and specific methodologies will most certainly vary depending on the plant extract and research objectives. Consulting with experts and referring to relevant literature is essential for a successful toxicity assessment. Altogen Labs provides plant extract toxicity testing services – contact us to receive a quote. Continue Reading
Altogen Labs in Therapeutic Oligonucleotide Patent Application
Dnai for the modulation of genes Aberrant gene expression, for example overexpression or expression of mutant genes and proteins, is the root cause of many diseases. Cancer is a result of aberrant cellular signaling that causes uncontrolled growth and proliferation; as a complex disease, combination proteins involving angiogenesis, epithelial to mesenchymal transition, tumor suppression, cell… Continue Reading
Acute Myeloid Leukemia (AML) Research Study
Publication [Download PDF]: MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood. 118(7):1899-902. doi: 10.1182/blood-2010-09-306258 Acute myeloid leukemia (AML) is a rapidly progressing cancer characterized by the abnormal buildup of myeloid cells that interfere with normal blood cell (red, white and platelet) function. There are certain genetic markers, for example monosomy 7 (–7) and… Continue Reading
Altogen Labs offers in vivo imaging services for drug development and biodistribution studies: Orthotopic glioma xenograft model
Altogen Labs provides in vivo imaging services for drug development and biodistribution studies: U87 orthotopic glioma xenograft animal model study by Altogen Labs, 11200 Manchaca Rd, Suite 203 Austin TX 78748 USA Download full text PDF: Introduction In vivo imaging has emerged as a critical tool in visualization in preclinical research studies related to the development… Continue Reading
Altogen Labs in the Investigation of miRNA expression of Acute Myeloid Leukemia
Publication [Download PDF]: Dmitriy Ovcharenko, Friedrich Stolzel, David Poitz, Fernando Fierro, Markus Schaich, Andreas Neubauer, Kevin Kelnar, Timothy Davison, Carsten Muller-Tidow, Christian Thiede, Martin Bornhauser, Gerhard Ehninger, David Brown, and Thomas Illmer. Experimental Hematology 2011; 39:1030–1042 Acute myeloid leukemia (AML) is a cancer that affects hematopoietic stem cells and often results in the accumulation of… Continue Reading
Alofanib Preclinical Research Study
Publication [Download PDF]: Tyulyandina, A., Harrison, D., Yin, W. et al. Invest New Drugs (2017) 35: 127. https://doi.org/10.1007/s10637-016-0404-1 Ovarian cancer is notorious for its poor prognosis; five-year survival rates for are 40% and 18% for stages III and IV, respectively. Ovarian cancer classifications are defined by the origin cell types and include papillary serous histology,… Continue Reading
Xenograft Models for Preclinical Research: From Translational Studies to Clinical Trials
AUSTIN, TX, December 17, 2018 Altogen Labs, a biotechnology laboratory focused on the development of innovative cancer therapeutics, today announced the addition of new CDX models (MDA-MB-157, MDA-MB-453, U87, and OVCAR-3). The addition of these xenograft models further increases Altogen Labs’ product line in breast and ovarian cancer, as well as glioblastoma to 89 CDX,… Continue Reading